Palatin Technologies Inc expected to post a loss of $1.20 a share - Earnings Preview
Palatin Technologies Inc expected to post a loss of $1.20 a share - Earnings Preview
Palatin Technologies Inc PTN.OQ PTN.O is expected to show a rise in quarterly revenue when it reports results on September 21 (estimated) for the period ending June 30 2026
The Cranbury New Jersey-based company is expected to report revenue of $1.25 million, according to the mean estimate from 2 analysts, based on LSEG data.
LSEG's mean analyst estimate for Palatin Technologies Inc is for a loss of $1.20 per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Palatin Technologies Inc is $53.00, about 408.1% above its last closing price of $10.43
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Mar. 31 2026 | -1.28 | -1.24 | -0.37 | Beat | 70.2 |
Dec. 31 2026 | -2.34 | -2.35 | -2.86 | Missed | -21.5 |
| |||||
-2.72 | |||||
Mar. 31 2025 | -8.50 | -8.50 | -9.00 | Missed | -5.9 |
Dec. 31 2024 | -21.00 | -21.00 | -6.00 | Beat | 71.4 |
Sep. 30 2024 | -25.50 | -25.50 | -19.50 | Beat | 23.5 |
Jun. 30 2024 | -27.75 | -25.00 | Beat | 9.9 |
This summary was machine generated September 18 at 11:31 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Recent news on Palatin Technologies
See all newsPalatin Technologies Inc reports results for the quarter ended March 31 - Earnings Summary
Palatin Technologies Inc expected to post a loss of $1.20 a share - Earnings Preview
Palatin Technologies Q2 revenue rises yr/yr, net loss widens
Brief: Palatin Announces 1-For-50 Reverse Stock Split
Brief: Palatin Announces Positive Preclinical Efficacy Data For Oral MC4R Agonist PL7737 In Animal Model Of Obesity